Tim Boreham
Columnist and Author at The New Criterion
Writer at Freelance
Freelance business scribe; author, The New Criterion column; author, Dr Boreham's Crucible (biotech stocks)
Articles
-
1 week ago |
stockhead.com.au | Tim Boreham
Amid one of the stock market’s worst downturns, investors again are turning negative after Thursday’s stalled comeback attempt. However, Australia could emerge surprisingly well if Trump’s punitive tariff measures are enactedThe key wildcard is how China – our biggest trading partner – faresAfter Donald Trump’s tariff backflip more impressive than Nadia Comaneci’s perfect effort on the gym mat, investors are confused.
-
2 weeks ago |
stockhead.com.au | Tim Boreham
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with Arovella Therapeutics (ASX:ALA) CEO and managing director Michael Baker. The cancer immunotherapy space has been a hub of activity in recent year, with many biotechs investing lots of money into developing CAR-T therapies, a type of immunotherapy that re-engineers a patient’s own T cells to target and destroy cancer cells.
-
2 weeks ago |
theaustralian.com.au | Tim Boreham
StockheadStockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with Arovella Therapeutics (ASX:ALA) CEO and managing director Michael Baker. The cancer immunotherapy space has been a hub of activity in recent year, with many biotechs investing lots of money into developing CAR-T therapies, a type of immunotherapy that re-engineers a patient's own T cells to target and destroy cancer cells.
-
2 weeks ago |
stockhead.com.au | Tim Boreham
Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariffFlu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund its superbug fightAs they say, a week is a long time in politics and Donald Trump’s bellicose Liberation Day words on tariffs now seem like a mealy-mouthed positioning statement.
-
2 weeks ago |
stockhead.com.au | Tim Boreham
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with AdAlta (ASX:1AD) CEO and managing director Dr Tim Oldham. For several years, AdAlta has been laser focused on its lead asset AD-214, an innovative first in class product for treating fibrotic diseases.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 833
- Tweets
- 493
- DMs Open
- No
Such is life … https://t.co/PL8hgYY6En
He started at the then Melbourne Sun in 1985 0r 1986, so to be a copyboy at the Age a decade later does not exactly do justice to his dazzling career trajectory ...
Some fact-checking required here from the Oz...on behalf of all those who studied and worked with the Cat in the 1980s https://t.co/9EF71v7DGr
https://t.co/e9VnrImbfY
